<!DOCTYPE html>
<html>

<head>
	<title>PAH Risk Calculator</title>
	<meta charset='UTF-8' />
	<meta name="viewport" content="width=device-width, user-scalable=no">
	<link rel="stylesheet" type="text/css" href="../utility/bootstrap/css/bootstrap.css">
	<link rel="stylesheet" type="text/css" href="../utility/style.css">
	<link rel="stylesheet" type="text/css" href="style.css">
	<link rel="stylesheet" media="print" href="print_style.css">
	<script type="text/javascript" src="../utility/utility.js"></script>
	<script type="text/javascript" src="RiskCalc.js"></script>
</head>

<body onload="createTable()">

	<header class="container">
		<div class="row">
			<nav class="col-xs-8 text-right">
			</nav>
		</div>
	</header>

	<section class="container">

		<table class="table table-bordered" id="mainTable">

			<tbody class="solid-border">
				<tr class="title-row">
					<th colspan="5">
						Pulmonary Arterial Hypertension Risk Score Calculator - 3-Strata Model
						<br>
						<small>Select the available risk category for each parameter</small>
					</th>
				</tr>
			</tbody>

			<tbody class="solid-border">
				<tr class="header-row">
					<th class="header-cell" colspan="2" rowspan="2" style="border: 2px solid black; font-size: 16px;">
						Determinants of prognosis
					</th>
					<th class="header-cell" colspan="3" style="border: 2px solid black;">
						Risk Group Corresponding to 1-year Mortality
					</th>
				</tr>

				<tr class="header-row">
					<th class="header-cell" style="width:180px;background-color: var(--low-green);">
						Low risk (<5%)
					</th>
					<th class="header-cell" style="width:180px;background-color: var(--mid-yellow);">
						Intermediate risk (5-20%)
					</th>
					<th class="header-cell" style="width:180px;background-color: var(--high-red);">
						High risk (>20%)
					</th>
				</tr>
			</tbody>


			<!-- Parameters go here -->
			<tbody class="solid-border" id="misc">
			</tbody>


			<!-- Start of result section -->
			<tr class="title-row">
				<th colspan="4">
					Calculated ESC/ERS Risk Scores <sup>1-14</sup>
				</th>
				<th>
					<button class="table-btn" onclick="resetCalc()">
						Reset
					</button>
				</th>
			</tr>

			<tr class="header-row">
				<th class="header-cell">N</th>
				<th class="header-cell">Risk Assesment Strategy</th>
				<th class="header-cell">Risk Score</th>
				<th class="header-cell" colspan="2">Key for Interpretation</th>
			</tr>

			<tr class="title-row">
				<th colspan="3">
					SPAHR-equation derived risk scores
				</th>
				<td colspan="2" rowspan="4" class="image-cell">
					<object data="img/int-key-4scale.svg" class="image-svg" width="100%" height="100%"></object>
				</td>
			</tr>

			<tr class="result-row">
				<td class="result-cell" id="result_Full_count">0/18</td>
				<td class="title-cell" onmouseenter="highlightParam('result_Full')" onmouseout="highlightParam()">
					Extended<small> (clinical observations and modifiable parameters)</small>
					<!--Using all available parameters-->
				</td>
				<td class="result-cell" id="result_Full">Use &geq; 3 parameters</td>
			</tr>

			<tr class="result-row">
				<td class="result-cell" id="result_SPAHR_count">0/8</td>
				<td class="title-cell" onmouseenter="highlightParam('result_SPAHR')" onmouseout="highlightParam()">
					SPAHR-Kylhammar <sup>¤</sup><!--<small> (up to 8 determinats of prognosis, marked ¤)</small>-->
				</td>
				<td class="result-cell" id="result_SPAHR">Use &geq; 3 parameters</td>
			</tr>

			<tr class="result-row">
				<td class="result-cell" id="result_Compera_count">0/6</td>
				<td class="title-cell" onmouseenter="highlightParam('result_Compera')" onmouseout="highlightParam()">
					COMPERA
					<sup>#</sup><!--<small> (up to 6 parameters marked ¤, without RA area and pericardial effusion)</small>-->
				</td>
				<td class="result-cell" id="result_Compera">Use &geq; 3 parameters</td>
			</tr>

			<tr class="title-row">
				<th colspan="5">
					French strategy - number of low-risk parameters
				</th>
			</tr>

			<tr class="result-row">
				<td class="result-cell" id="result_french1_count">0/4</td>
				<td colspan="3" class="title-cell" onmouseenter="highlightParam_f('result_french1')"
					onmouseout="highlightParam_f()">
					French invasive<small> (WHO-FC, 6MWD, RAP, CI)</small>
				</td>
				<td class="result-cell" id="result_french1">Use 4 parameters</td>
			</tr>

			<tr class="result-row">
				<td class="result-cell" id="result_french2_count">0/3</td>
				<td colspan="3" class="title-cell" onmouseenter="highlightParam_f('result_french2')"
					onmouseout="highlightParam_f()">
					French non-invasive<small> (WHO-FC, 6MWD, BNP/NT-proBNP)</small>
				</td>
				<td class="result-cell" id="result_french2">Use 3 parameters</td>
			</tr>

		</table>

		<!-- Collapsible enviroment with extra information -->
		<button class="collapsible" onclick="collapseContent(this)">Click to show Additional Information</button>
		<div id="info" class="collapsible-content">
			<p style="font-weight: bold;">By using the PAH risk score calculator the user agrees and consents to be bound to
				the terms of use, as follows:</p>
			<ul>
				<li>
					The risk score calculator variables and cut-offs were initially based on expert opinion according to the 2015
					ESC/ERS pulmonary hypertension guidelines, [1,2] and have thereafter been validated in a series of studies,
					[5-13] and further expanded in the 2022 ESC/ERS pulmonary hypertension guidelines. [3,4]
				</li>

				<li>
					The risk score calculator assists in the calculation of risk scores, but is not intended to replace general
					clinical assessment, judgement, or treatment decisions.
				</li>
				<li>
					N indicates the number of parameters used in the risk score calculation.
				</li>
				<li>
					The user takes full responsibility, for all data input, calculated risk scores, and decision making.
				</li>
				<li>
					The developers are not liable for any errors or inaccuracies in the algorithms or content within or related to
					the calculation tool.
				</li>
				<li>
					The final decision making has to be made by the user on a comprehensive and balanced clinical judgement in
					relation to the clinical presentation. The risk score calculator serves only as a supporting tool.
				</li>
				<li>
					The risk score calculator may be updated in accordance with the prevailing ESC/ERS guidelines.
				</li>
			</ul>

			<p style="font-weight: bold;">The SPAHR-Kylhammar equation for the SPAHR three-strata model without and with
				divided intermediate risk group</p>
			<p>The SPAHR equation was initially described by Kylhammar et al, assessing a score of 1, 2 or 3, to each
				parameter depending on the thresholds defined by the 2015 ESC/ERS guidelines. The sum is divided by the numbers
				of parameters included, and thereafter rounded off to the nearest integer. [1,2,5]</p>
			<p>The original SPAHR three-strata model categorizes patients into low, intermediate, or high risk for one year
				mortality, by assigning a score <br>(low risk = 1, intermediate risk = 2 and high risk = 3) to parameters based
				on thresholds defined initially by the 2015 and subsequently by the 2022 ESC/ERS guidelines. The overall risk
				category (low risk, intermediate risk, or high risk) is determined by the average from the scores of the
				available parameters for each patient, rounded off to the nearest integer (1 - 1.49 = low risk, 1.5 - 2.49 =
				intermediate risk, and ≥ 2.5 high-risk). [1-5]</p>
			<p>In the new updated SPAHR three-strata model with divided intermediate risk group, the calculated mean is
				rounded off according to modified thresholds for the intermediate risk (1.5 - 1.99 = intermediate-low risk, 2.0
				- 2.49 = intermediate-high risk; instead of 1.5 - 2.49 = intermediate risk in the original SAPHR three-strata).
				[9]</p>
			<p>The SPAHR-Kylhammar three-strata strategies may be used at diagnosis and at follow-up. To allow a simplified
				and more granular method at follow-up, the new four-strata strategy based on the COMPERA 2.0 three-parameter
				model (WHO-FC, 6MWD, BNP/ NT-pro-BNP) may be used. A more comprehensive and precise long-term prognostic
				prediction can, however, be achieved by using additional prognostic parameters, applying the updated SPAHR
				three-strata strategy, with divided intermediate risk group. [3,4,10,11,12]</p>

			<p style="font-weight: bold;">The French invasive and non-invasive model</p>
			<p>The invasive and non-invasive French pulmonary hypertension registry based models complies the number of
				low-risk criteria achieved, as defined by the 2015 ESC/ERS risk stratification strategy. Notably, the number of
				low risk criteria cannot be interpreted into three different risk categories, i.e low-, intermediate-, and high
				risk.</p>


			<b style="font-size: 20px;">*</b><small> Note that if both NT-proBNP and BNP are selected, only NT-proBNP will be
				included in the calculated risk score.</small>
			<br>
			<b>¤</b><small> Indicates the parameters used in the SPAHR-Kylhammar equation, including; WHO-FC, 6MWD,
				BNP/NT-proBNP, RA area, pericardial effusion, RAP, CI, and
				S<sub>V</sub>O<sub>2</sub>.<!--In COMPERA, RA area and pericardial effusion are not included.--></small>
			<br>
			<b>#</b><small> Indicates the parameters used in the initial COMPERA model, including; WHO-FC, 6MWD,
				BNP/NT-proBNP, RAP, CI, and S<sub>V</sub>O<sub>2</sub>.
		</div>

		<!-- Collapsible enviroment with article references -->
		<button class="collapsible" onclick="collapseContent(this)">Click to show References</button>
		<div id="ref" class="collapsible-content">
			<ol>
				<li>Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A,
					Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T,
					Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of
					pulmonary hypertension. <i>European Respiratory Journal</i> 2015; <b>46</b>:903.</li>

				<li>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A,
					Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T,
					Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 esc/ers guidelines for the diagnosis and treatment of
					pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the
					european society of cardiology (esc) and the european respiratory society (ers): Endorsed by: Association for
					european paediatric and congenital cardiology (aepc), international society for heart and lung transplantation
					(ishlt). <i>Eur Heart J</i> 2016; <b>37</b>:67-119.</li>

				<li>Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias
					P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM,
					Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf
					A, Delcroix M, Rosenkranz S, Group EESD. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
					hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the
					European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International
					Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory
					diseases (ERN-LUNG). <i>European Heart Journal</i> 2022: ehac237.
				</li>

				<li>
					Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P,
					Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM,
					Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery J-L, Vonk Noordegraaf
					A, Delcroix M, Rosenkranz S. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary
					hypertension. <i>European Respiratory Journal</i> 2022: 2200879.
				</li>

				<li>Kylhammar D, Kjellström B, Hjalmarsson C, Jansson K, Nisell M, Söderberg S, Wikström G, Rådegran G. A
					comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension.
					<i>Eur Heart J</i> 2018; <b>39</b>: 4175-4181.
				</li>

				<li>Boucly A, Weatherald J, Savale L, Jaïs X, Cottin V, Prevot G, Picard F, de Groote P, Jevnikar M, Bergot E,
					Chaouat A, Chabanne C, Bourdin A, Parent F, Montani D, Simonneau G, Humbert M, Sitbon O. Risk assessment,
					prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i>
					2017; <b>50</b>:1700889.</li>

				<li>Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, Olsson KM, Meyer K, Vizza CD,
					Vonk-Noordegraaf A, Distler O, Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Huscher D, Pittrow D, Rosenkranz
					S, Grünig E. Mortality in pulmonary arterial hypertension: Prediction by the 2015 european pulmonary
					hypertension guidelines risk stratification model. <i>Eur Respir J</i> 2017; <b>50</b></li>

				<li>Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, McGoon MD, Pasta DJ, Selej M,
					Burger CD, Frantz RP. Predicting survival in patients with pulmonary arterial hypertension: The reveal risk
					score calculator 2.0 and comparison with esc/ers-based risk assessment strategies. <i>Chest</i> 2019;
					<b>156</b>:323-337.
				</li>

				<li>Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M, Kjellström B, Nisell M, Söderberg S,
					Rådegran G. Predicting mortality during long-term follow-up in pulmonary arterial hypertension. <i>ERJ Open
						Research</i> 2021; <b>7</b>:00837-02020.</li>

				<li>Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grünig E, Staehler G, Vizza CD, Gall H, Distler O,
					Opitz C, Gibbs JSR, Delcroix M, Ghofrani HA, Park D-H, Ewert R, Kaemmerer H, Kabitz H-J, Skowasch D, Behr J,
					Milger K, Halank M, Wilkens H, Seyfarth H-J, Held M, Dumitrescu D, Tsangaris I, Vonk-Noordegraaf A, Ulrich S,
					Klose H, Claussen M, Lange TJ, Rosenkranz S. Compera 2.0: A refined four-stratum risk assessment model for
					pulmonary arterial hypertension. <i>European Respiratory Journal</i> 2022; <b>60</b>:2102311.</li>

				<li>Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, Chaouat A, Picard F, Horeau-Langlard D,
					Bourdin A, Jutant E-M, Beurnier A, Jevnikar M, Jaïs X, Simonneau G, Montani D, Sitbon O, Humbert M. External
					validation of a refined four-stratum risk assessment score from the french pulmonary hypertension registry.
					<i>European Respiratory Journal</i> 2022; <b>59</b>:2102419.
				</li>

				<li>Ahmed A, Ahmed S, Kempe D, Rådegran G. Evaluation of the European Society of Crdiology-/European Respiratory
					Society-derived three- and four-strata risk stratification models in pulmonary arterial hypertension:
					introducing an internet-based risk stratification calculator, <i>European Heart Journal Open,</i>2023.</li>

				<li>Dardi F, Boucly F, Benza R, Frantz R, Mercurio V, Olschewski H, Rådegran G, Rubin Lewis J, Hoeper MM. Risk
					stratification and treatment goals in pulmonary arterial hypertension, <i>European Respiratory
						Journal,</i>2024; DOI: 10.1183/13993003.01323-2024
				</li>

				<li>
					<!-- Authors -->
					Sahay S, Visovatti S, Tonelli AR, Villasmil Hernandez N, Austin ED, Badagliacca R, Berger RMF, Boucly A, Chen Y,
					Church C, Delcroix M, Everett AD, Farber HW, Fauvel C, Gomberg-Maitland M, Griffiths M, Haddad F, Han Y, Hemnes A,
					Hoeper MM, Kanwar MK, Lachant D, Murthy S, Olsson KM, Preston I, Rådegran G, Sitbon O, Trivieri MG, Vachiery J-L, Vanderpool R,
					Weatherald J, White RJ, Whitford H, Wilson M, L. Benza R.
					<!-- Title -->
					International society for heart and lung transplantation (ishlt) consensus statement on risk stratification in pulmonary arterial hypertension.
					<!-- Journal -->
					Journal of Heart and Lung Transplantation. doi: 10.1016/j.healun.2025.04.015. Epub 2025 Sep 05.
				</li>

			</ol>
		</div>

		<footer class="page-footer" style="min-height: 50px; margin-top: auto;">
			<div class="footer-copyright text-center py-3">
				Developed by Abdulla Ahmed, Daniel Kempe, Salaheldin Ahmed, and Göran Rådegran
			</div>
		</footer>

	</section>


</body>